IRLAB Therapeutics AB
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From IRLAB Therapeutics AB
Irlab Parkinson's Pact With Ipsen Up In The Air
The Swedish firm’s Parkinson's disease drug has failed to hit its primary endpoint in a Phase IIb study but Irlab believes that positive results on secondary goals merit further development of mesdopetam.
Pivotal Period For Irlab And Its Parkinson’s Pipeline
The Swedish biotech is well positioned with soon-to-be late-stage clinical assets, commercial validation and a strong pipeline, new CEO Richard Godfrey tells Scrip.
Ipsen Expands In Oncology With New Pacts
After CEO David Loew declared again that Ipsen would be very active in the dealmaking space, Ipsen is paying $45m upfront to access two immuno-oncology candidates from Marengo and bagged an ERK inhibitor from AGV Discovery.
Ipsen Hungry For More Deals After Swallowing Epizyme
Ipsen CEO David Loew recently told Scrip that a return to more rational valuations for biotechs should led to more deals. The Epizyme acquisition could be the first of many by the French group this year.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.